Article Text

PDF
Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond
  1. W M Kooloos1,
  2. J A M Wessels1,
  3. S M van der Kooij2,
  4. C F Allaart2,
  5. T W J Huizinga2,
  6. H-J Guchelaar1
  1. 1
    Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
  2. 2
    Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  1. W M Kooloos, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600, NL 2300 RC Leiden, The Netherlands; w.m.kooloos{at}lumc.nl

Statistics from Altmetric.com

Several single nucleotide polymorphisms (SNP) have been reported to be associated with the efficacy of methotrexate in the treatment of rheumatoid arthritis (RA).1 2 Subsequently, we developed a clinical model to predict the efficacy of methotrexate monotherapy in patients with recent-onset RA (N  =  205).3 The model consists of non-genetic factors, sex, rheumatoid factor and smoking status, disease activity score (DAS) before starting methotrexate and four genetic polymorphisms (MTHFD1 1958G>A, AMPD1 34C>T, ITPA 94A>C and ATIC 347C>G). Associations of these factors with the response to methotrexate were transformed into a scoring system ranging from 0 to 11.5 points. The predictive model showed a positive predictive value of 95% and a negative predictive value of 86% and was able to categorise 60% of …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.